[ad_1]
In Thessaloniki, researchers identified a genetic mutation coronavirus.
Genetic mutation coronavirus which has a double effect on patients, was in Thessaloniki.
Specifically, a study in the Molecular Biology Laboratory of the Papanikolaou Hospital Hematology Clinic, found that people in whom a combination of mutations has been observed can develop a severe form of Covid-19 and be hospitalized in the Unit. Intensive Care.
However, there are individuals in whom a variation in the CFB gene (rs641153) has been observed that may be protective.
The new data will be presented at the annual conference of the American Hematological Society next November and will be published in the journal “Blood.”
In fact, the researcher-hematologist of the Papanikolaou Hematology Clinic, Eleni Gavriilaki, spoke with APE-MPE and stated that if patients are identified who are predisposed to a very serious infection by Covid-19, they can benefit from a treatment directed with which is currently indicated for hematological diseases. The supplement, as explained by Ms Gavriilaki, is a mechanism by which inflammation occurs, that is, the infection for which the SARS-COV-2 virus is responsible and in patients who are predisposed there is an inactivation of the supplement and is therefore investigating whether you can treat them with supplement inhibitors.
Thus, in the context of the research, a new genetic method was studied, the sequencing of a new generation, 60 patients with Covid-19 infection, of which 40, with moderate disease, were treated at the Pulmonary and Pathology Clinics and 20, with serious illness. , in the ICUs of the Papanikolaou and Attikon hospitals, in the period April – May 2020. The study was carried out to determine if there is a genetic predisposition, that is, if there is any mutation that causes patients to have a serious infection, become seriously ill and are admitted to the ICU. .
“We did this research because we believe that a patient who does not have a known predisposing factor (eg diabetes, hypertension, etc.), for some reason, can be taken to the ICU and another person can get a very mild illness without symptoms. We found that there are some mutations in complement genes, which when combined are significantly related to the likelihood of being admitted to the ICU. Therefore, as studies with supplement blockers continue around the world, we believe that by By controlling these mutations, we can more quickly find patients who might benefit from supplement blockers. And this is very important because it is a relatively expensive treatment that may not be available to a large number of patients worldwide. “That is why we believe that By selecting these patients through genetic testing, we will be able to find those who could benefit from treatment with inh supplements, which has an indication for hematological diseases, ”explains Ms Gavriilaki.
Additionally, the supplement’s inhibitors, as Ms. Gavriilaki mentions, are biological agents circulating through pharmaceutical companies and some have received an indication of a hematologic disease, while there are some that are under study. That is to say, these are drugs that are used for hematological diseases and can be used in patients with Covid who have mutations that predispose them to develop a severe form of the disease.
ΑΠΕ-ΜΠΕ Information
[ad_2]
